The acute myeloid leukemia (AML) survival rate by age falls steeply as age rises. Children and adolescents do best, with roughly two in three surviving five years or more. Adults under about 60 who can receive intensive treatment have intermediate outcomes, and people over 65, who make up most AML cases, have the lowest long-term survival. Age matters largely because of what comes with it: harder-to-treat leukemia genetics and less ability to tolerate intensive therapy.
Survival statistics describe large groups, not individuals. In my practice, the genetic profile of the leukemia and a patient’s overall fitness often tell me more than the birth date on the chart. This article explains the age pattern and the factors behind it.
What Is Acute Myeloid Leukemia?
Acute myeloid leukemia is a fast-growing cancer of the myeloid cells in the bone marrow, the cells that normally become red blood cells, platelets, and several kinds of white blood cells. Immature cells called blasts multiply and crowd out normal production, causing bone marrow failure: anemia, infections, and bleeding.
AML is diagnosed with a blood count, a bone marrow biopsy, flow cytometry, and genetic testing. It is mainly a disease of older adults; the median age at diagnosis is in the late 60s. It sits among the many hematological disorders that a hematologist treats, and is distinct from acute lymphocytic leukemia, whose survival factors are covered in our article on acute lymphocytic leukemia survival.
AML Survival Rate by Age Group
The figures below are broad approximations of five-year survival drawn from large cancer registries. They lag behind current treatment by several years and vary between countries and centers.
| Age group | Approximate five-year survival | Main reasons |
|---|---|---|
| Children and adolescents (under 20) | Around two in three | Favorable genetics more common; tolerate intensive chemotherapy and transplant |
| Younger adults (20–59) | Roughly one-third to one-half | Most can receive intensive therapy; outcome depends heavily on genetic risk |
| Adults 60–69 | Lower; roughly one in five or fewer | More adverse genetics and other health conditions |
| Adults 70 and older | Low; under one in ten | Adverse biology, frailty, and limited eligibility for intensive treatment or transplant |
Across all ages combined, about three in ten people with AML are alive five years after diagnosis. For how these numbers compare with other leukemias, see our overview of leukemia survival rates.
Why Age Changes the Outlook
Disease biology
AML in older adults more often carries adverse-risk genetics: a complex karyotype, TP53 mutations, or changes in chromosomes 5 and 7. It also more often develops from a prior marrow disorder such as myelodysplastic syndrome, or after chemotherapy for another cancer. These forms respond less well to treatment and relapse more often.
Younger patients, by contrast, more often have favorable-risk abnormalities such as t(8;21), inv(16), or an NPM1 mutation without a high-level FLT3 mutation.
Fitness for treatment
Intensive induction chemotherapy causes weeks of profound low blood counts. Heart, kidney, and lung problems, which become more common with age, make that period riskier. An older patient may be ineligible for intensive chemotherapy or for a stem cell transplant, the most effective way to prevent relapse in higher-risk disease.
Performance status
How active and independent a person is, known as performance status, predicts tolerance of treatment. A fit 72-year-old may do better than a frail 60-year-old, which is why age alone should never be the only factor in treatment decisions.
Genetic Risk Groups Matter at Every Age
Doctors classify AML using the European LeukemiaNet (ELN) risk categories, based on chromosome and gene findings.
| Risk group | Examples | General outlook |
|---|---|---|
| Favorable | t(8;21), inv(16), mutated NPM1 without FLT3-ITD, in-frame CEBPA mutations | Best chance of cure with chemotherapy |
| Intermediate | Normal karyotype with FLT3-ITD, other abnormalities not in the other groups | Transplant often considered in first remission |
| Adverse | Complex karyotype, TP53 mutation, monosomy 7, inv(3) | Highest relapse risk; transplant if eligible |
A special subtype, acute promyelocytic leukemia (APL), deserves mention. Treated promptly with all-trans retinoic acid and arsenic trioxide, it has high cure rates, including in many older adults.
How Treatment Differs by Age
Fit younger adults usually receive intensive induction chemotherapy (“7+3” cytarabine and an anthracycline), followed by consolidation chemotherapy or an allogeneic transplant. Targeted drugs are added for specific mutations, such as FLT3 inhibitors.
For older or less fit patients, the combination of venetoclax with a hypomethylating agent (azacitidine or decitabine) has become a standard lower-intensity option. It has improved remission rates compared with a hypomethylating agent alone and is given as an outpatient in many cases. Drugs targeting IDH1 and IDH2 mutations add further choices. Reduced-intensity transplants have extended transplant eligibility into older age for selected patients.
Our articles on improving acute myeloid leukemia survival and advances in leukemia treatment discuss these developments further.
Key Takeaways
- AML survival declines with age, from about two in three in children to under one in ten in people over 70.
- Age acts through leukemia genetics and fitness for treatment, not simply the number of years.
- Genetic risk group is one of the strongest predictors at every age.
- Newer low-intensity combinations have widened options for older adults.
- Published statistics lag behind current therapy, so individual outlook should be discussed with your hematologist.
Families looking for practical support can start with our guide for patients and caregivers facing hematological disorders, and our leukemia guide covers the other leukemia types.
Frequently Asked Questions
What is the survival rate for AML in people over 60?
Long-term survival is lower than in younger adults, generally around one in five or fewer at five years for people in their 60s, and lower again after 70. Fitness, genetics, and transplant eligibility produce wide variation within this group.
Is AML curable in older adults?
It can be, particularly in fit patients with favorable genetics or APL, and in those who can undergo a reduced-intensity transplant. For many others, treatment aims to achieve remission and extend good-quality life.
Why do children with AML have better survival?
Children more often have favorable genetic subtypes, rarely have other illnesses, and tolerate intensive chemotherapy and transplant well. Our article on myeloid leukemia survival rates discusses childhood outcomes in more detail.
Do survival rates reflect today’s treatments?
Not entirely. Five-year figures describe people diagnosed at least five years ago, before some newer therapies were widely used. For more on how to read these numbers, see insights into leukemia survival rates.
